Cellectar Biosciences, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies.
The company announced in the following press release that, “CLR 1603-PTX in vivo safety and efficacy evaluation will now be conducted in animal tumor models in order to demonstrate the chemotherapeutic payload targeting efficacy of the PDC delivery platform.” Read the full article.
Cellectar BioSciences, Inc. operates as a biopharmaceutical company. It engages developing phospholipid drug conjugates designed to provide cancer targeted delivery of oncologic payloads to cancer stem cells. The company was founded on April 11, 2011 and is headquartered in Madison, WI. [Source: MarketWatch]
Company Website: http://cellectar.com